CD274 and neoplasm: The outcomes demonstrated significant tumor growth inhibition in the OE-NC group subjected to the combined treatment of RGX104 and anti-PD-L1, as well as in the OE-Apoe RM-1 group treated with anti-PD-L1, contrasting with the OE-NC group treated with anti-PD-L1 alone.